Samuel S - Search Results

1

Allogeneic cell-mediated and cytokine-activated immunotherapy for malignant lymphoma at the stage of minimal residual disease after autologous stem cell transplantation.

Or R, Ackerstein A, Nagler A, Amar A, Naparstek E, Varadi G, Kapelushnik J, Samuel S, Pugatsch T, Brautbar C, Slavin S. Or R, et al. Among authors: samuel s. J Immunother. 1998 Nov;21(6):447-53. doi: 10.1097/00002371-199811000-00007. J Immunother. 1998. PMID: 9807740 Clinical Trial.

2

Effects of interleukin 2 on engraftment following autologous bone marrow transplantation (ABMT) in dogs.

Samuel S, Nagler A, Or R, Slavin S. Samuel S, et al. Leuk Res. 1992 Oct;16(10):967-72. doi: 10.1016/0145-2126(92)90075-i. Leuk Res. 1992. PMID: 1405710

3

Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J, Brautbar C, Or R. Slavin S, et al. Among authors: samuel s. Blood. 1996 Mar 15;87(6):2195-204. Blood. 1996. PMID: 8630379 Free article.

4

Second transplantation using allogeneic peripheral blood stem cells in a beta-thalassaemia major patient featuring stable mixed chimaerism.

Or R, Kapelushnik J, Naparstek E, Nagler A, Filon D, Oppenheim A, Amar A, Aker M, Samuel S, Slavin S. Or R, et al. Among authors: samuel s. Br J Haematol. 1996 Aug;94(2):285-7. doi: 10.1046/j.1365-2141.1996.d01-1797.x. Br J Haematol. 1996. PMID: 8759888

5

Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.

Kapelushnik J, Nagler A, Or R, Naparstek E, Ackerstein A, Samuel S, Morecki S, Nabet C, Slavin S. Kapelushnik J, et al. Among authors: samuel s. Bone Marrow Transplant. 1996 Dec;18(6):1153-6. Bone Marrow Transplant. 1996. PMID: 8971387

6

Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.

Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, Varadi G, Kirschbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tal O, Eldor A, Or R. Slavin S, et al. Among authors: samuel s. Blood. 1998 Feb 1;91(3):756-63. Blood. 1998. PMID: 9446633 Free article.

7

Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study.

Or R, Ackerstein A, Nagler A, Kapelushnik J, Naparstek E, Samuel S, Amar A, Bruatbar C, Slavin S. Or R, et al. Among authors: samuel s. Cytokines Cell Mol Ther. 1998 Mar;4(1):1-6. Cytokines Cell Mol Ther. 1998. PMID: 9557210 Clinical Trial.

8

Bone marrow transplantation from a cadaveric donor.

Kapelushnik J, Aker M, Pugatsch T, Samuel S, Slavin S. Kapelushnik J, et al. Among authors: samuel s. Bone Marrow Transplant. 1998 Apr;21(8):857-8. doi: 10.1038/sj.bmt.1701165. Bone Marrow Transplant. 1998. PMID: 9603417

9

Engraftment following mitoxantrone (Mito) based conditioning for allogeneic bone marrow transplantation (allo-BMT).

Nagler A, Soni S, Samuel S, Or R. Nagler A, et al. Among authors: samuel s. Leuk Res. 1998 Mar;22(3):209-13. doi: 10.1016/s0145-2126(97)00175-6. Leuk Res. 1998. PMID: 9619912 Clinical Trial.

10

Selective CD4+ T-cell depletion does not prevent graft-versus-host disease.

Nagler A, Condiotti R, Nabet C, Naparstek E, Or R, Samuel S, Slavin S. Nagler A, et al. Among authors: samuel s. Transplantation. 1998 Jul 15;66(1):138-41. doi: 10.1097/00007890-199807150-00025. Transplantation. 1998. PMID: 9679838

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,045 results

Search Page

Filters